Form 4: United Therapeutics CFO Executes Stock Option Plan

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

Summary

• CFO James Edgemond exercised 10,000 stock options at a strike price of $117.76.
• Following the exercise, the reporting person sold 10,000 shares of common stock in multiple transactions.
• The sales occurred at weighted average prices ranging from $544.93 to $551.76 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan established on October 31, 2025.
• The reporting person's direct beneficial ownership of common stock stands at 18,876 shares following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine, pre-planned divestment by an executive rather than a strategic shift or market-moving event.

Positives

• The transactions were executed under a pre-established Rule 10b5-1 plan, indicating a systematic approach to equity management rather than reactive selling.
• The exercise of options demonstrates the executive's long-term participation in the company's equity incentive programs.

Negatives

• The transaction results in a reduction of the CFO's direct equity stake in the company.

Risks

• None identified; this is a routine disclosure of executive compensation and equity management.

Future Outlook

No forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine 10b5-1 plan executions by C-suite executives are standard corporate governance practices and generally do not signal changes in company fundamentals or management sentiment.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to sell shares while avoiding potential accusations of insider trading.
• The volume of shares sold relative to the total holdings is consistent with typical executive diversification strategies in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as the transactions were conducted via a pre-arranged plan.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, CFO, Stock Options, 10b5-1